Vericel Corporation (Nasdaq: VCEL) 95.7% HIGHER; announced top-line results from the company’s Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE